Participant flow

Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma · Source last updated 2021-03-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   New diagnosis, high risk smoldering MM, relapse as defined by investigator. Participants received 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant received both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups. Fludeoxyglucose: Route of administration was intravenous. Dose of each injection was the standard 5 to 10 millicurie (mCi). Sodium Acetate C11: Route of administration was intravenous. Dose of each injection was 10 mCi (370 MBq).

   id

   FG000

   title

   Multiple Myeloma (MM) Patients

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Machine malfunction Day 1, no return Day 2

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      opted out of the study once his clinical FDG PET CT was done.

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      opted out of PET/MR

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         10

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         7

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice